Afatinib [20 mg, 30 mg, and 40 mg film-coated tablet] for the treatment of locally advanced or metastatic EGFR-positive Non-Small Cell Lung Cancer (NSCLC)
Cycle 4 | DrugsHTA Council Recommendation (as of 12 March 2026)
As a final recommendation, the HTA Council recommends the government financing Afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for first-line therapy of patients with EGFR-positive advanced or metastatic NSCLC. Afatinib is recommended for EGFR exon 19 deletion or exon 21 L858R mutation. Additionally, it is preferred for EGFR S768I, L861Q, and/or G719X mutations.
Relevant Information
- Status: With Final HTA Council Recommendation and SOH Decision
- Topic Assignment: Internal Assessment
- Policy Question: Should afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for first-line therapy of patients with EGFR-positive advanced or metastatic NSCLC be funded by the government?
- Secretary of Health Decision: Approved as of 30 April 2026
Evidence and Relevant Documents